Agios Pharmaceuticals shares jumped 14% after the FDA approved AQVESME, its oral therapy for anemia in adults with alpha- or beta-thalassemia. The approval was backed by Phase 3 ENERGIZE trials. Bank of America raised its price target to $34, citing the drugs' first-in-class status.